8-K: AIM ImmunoTech Regains NYSE American Compliance Following 1-for-100 Reverse Stock Split

AIM ImmunoTech Inc. announced it has regained compliance with NYSE American listing standards and will resume trading on the exchange on June 17, 2025, following a 1-for-100 reverse stock split.

Summary

• AIM ImmunoTech Inc. (AIM) was notified by NYSE American on June 11, 2025, that it has regained compliance with Section 1003(f)(v) of the NYSE American Company Guide, related to low selling price.
• Trading in the company's Common Stock is expected to be reinstated on the NYSE American on June 17, 2025, under the ticker symbol AIM.
• The company's Common Stock currently trades on the OTC Pink under the symbol AIMID.
• On June 10, 2025, the company filed an amendment to its Articles of Incorporation to effect a 1-for-100 reverse split of its outstanding shares of Common Stock.
• The reverse stock split became effective at market open on June 12, 2025.
• Stockholders authorized the Board of Directors to effect a reverse split up to 1-for-100 at a Special Meeting on April 30, 2025, and the Board authorized the split on May 29, 2025.
• Stockholders will receive cash in lieu of any fractional shares on a post-split basis.
• The new CUSIP number for the common stock is 00901B303, and the par value per share remains $0.001.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a reverse split indicates past stock price weakness, successfully regaining NYSE American compliance and avoiding delisting is a significant positive event for the company's market presence and investor confidence.

Positives

• The company has successfully regained compliance with NYSE American listing standards, preventing delisting.
• Trading of AIM's common stock is expected to resume on the NYSE American, which typically offers greater liquidity and visibility compared to OTC markets.

Negatives

• The company was required to implement a 1-for-100 reverse stock split to increase its per-share market price, indicating a history of low stock price performance.
• The stock temporarily traded on the OTC Pink under the symbol AIMID, which can be associated with lower investor confidence and liquidity.

Risks

• Forward-looking statements involve risks, uncertainties, and other factors that may cause actual results to be materially different from expectations.
• Data, pre-clinical success, and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in any indication.
• Investors are urged to consider specific risk factors identified in the company's most recent Form 10-K and any subsequent Form 10-Q or Form 8-K filings with the SEC.

Future Outlook

The company expects its common stock to resume trading on the NYSE American on June 17, 2025, under the symbol AIM, having resolved its low selling price compliance issue. The company continues its focus on the research and development of therapeutics, with Ampligen as its lead investigational drug.

Management Comments

• Thomas K. Equels, CEO, signed the report on behalf of AIM ImmunoTech Inc.

Industry Context

For biotechnology and pharmaceutical companies, maintaining listing on major exchanges like the NYSE American is crucial for investor visibility, access to capital, and perceived stability. Companies often resort to reverse stock splits to meet minimum bid price requirements, a common challenge for smaller or developing firms in the industry, especially those with long R&D cycles and no immediate revenue streams from approved products.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience a reduction in the number of shares held, but a proportional increase in share price. Fractional shares will be cashed out. Regaining NYSE listing may improve liquidity and investor confidence.
• Investors: The return to NYSE American trading may make the stock more attractive to institutional investors and increase its visibility.

Next Steps

• The company's common stock is expected to resume trading on the NYSE American on Tuesday, June 17, 2025, under the symbol AIM.

Key Dates

Keywords

AIM ImmunoTech, Reverse Stock Split, NYSE American, Listing Compliance, Ampligen, Biotechnology, Immuno-pharma, SEC Filing, Form 8-K, Stock Trading